Racura Oncology (RAC) Q1 2027 TU earnings summary

Executive summary

• Clinical programs advanced: HARNESS-1 and CPACS cleared their first dose cohorts without dose-limiting toxicities; cash was $30.7m at quarter end.

• Management expects the cash balance to fund committed activities into mid-CY2028.

Financial highlights

• Cash and cash equivalents were $30.735m at 30 September 2026, down from $34.290m at the prior quarter end.

• Net operating cash outflow was $3.542m; interest received was $496k and government grants and tax incentives were $115k.

• FY2025 R&D Tax Incentive refunds totalled $2.905m, including a further $117,875 refund for eligible overseas R&D.

Outlook and guidance

• Cash was estimated to provide 8.68 quarters of funding; management expects funding for committed activities into mid-CY2028.

• After quarter end, HARNESS-1 was cleared to escalate RC220 to 100 mg/m²; CPACS progressed to its next dose level.